Posted by Michael Wonder on 07 Aug 2024
Meta Pharmaceuticals announces FDA grants rare paediatric disease designation to META-001-PH for the treatment of primary hyperoxaluria
5 August 2024 - META Pharmaceuticals Inc. announced that the US FDA has granted rare paediatric disease designation to its investigational new drug META-001-PH for the treatment of primary hyperoxaluria.
META-001-PH is a groundbreaking small molecule drug developed by META for the treatment of primary hyperoxaluria
